Kornimate/medical-research-clean huggingface dataset:
working with hiv clinics to adopt addiction treatments using implementation facilitation

Conditions: Substance-related Disorders

Summary: tobacco, alcohol and opioid use disorders threaten the health of hiv-infected patients. what if evidence-based counseling and medication treatments for tobacco, alcohol and opioid use disorders (herein refered to as addiction treatments) were routinely provided in hiv clinics? implementation facilitation is an established strategy to increase the uptake of evidence-based treatments. our goal is to evaluate the impact of implementation facilitation on the use of addiction treatments in four large hiv clinics. the purpose of the what-if study is: aim 1. among key stakeholders, to use quantitative and qualitative (mixed) methods to identify the site-specific evidence, context and facilitation-related barriers and facilitators to the integration of addiction treatments to help tailor an implementation facilitation for each clinic. aim 2. to evaluate the impact of implementation facilitation on: 2a: organizational readiness to deliver addiction treatments 2b: provider readiness to deliver addiction treatments 2c: provision of addiction treatments 2d: changes in organizational models of care used to deliver addiction treatments aim 3. to evaluate the impact of implementation facilitation on antiretroviral therapy receipt, hiv viral suppression, vacs index, and retention in hiv care among patients eligible for addiction treatment.

the working with hiv clinics to adopt addiction treatments using implementation facilitation (what if?) study will evaluate the impact of implementation facilitation on the adoption of addiction treatment services in four hiv clinics. we will use a stepped wedge design . the primary comparison is of the change that occurs from the pre-implementation period to two post-implementation periods, the initial six months (evaluation) and the following six months (maintenance). this proposal will consist of three main components in each of four clinics: 1) formative evaluation with key stakeholders at each site to guide and refine the implementation facilitation, 2) conduct of the implementation facilitation and 3) an evaluation of the impact of the implementation facilitation on organization and provider-level readiness, provision of addiction treatments, and hiv outcomes.

Eligibility criteria:
inclusion criteria: patient inclusion criteria: * hiv-infected * receiving hiv care in the index clinic * age \>18 years old * meets criteria for lifetime or current tobacco, alcohol and/or opioid use disorder regardless of addiction treatment status * able to provide verbal informed consent staff inclusion criteria: * employed at participating hiv clinic for at least 6 months * able to provide verbal informed consent. payer/health insurance provider inclusion criteria: * employed at an organization or agency that provides funding for medical services for hiv-infected individuals for at least 6 months. * able to provide verbal informed consent. exclusion criteria: * unable to provide verbal informed consent
efficacy of brief mindfulness based self- compassion intervention for management of anger among adolescents

Conditions: Aggression

Summary: this study investigates the effectiveness of a short self-compassion mental intervention in reducing aggression among adolescents. although they display potential, current solutions are arduous and time-consuming. the study provides preliminary results on the effectiveness of this method in addressing the lack of information. the intervention's simplicity and precision have the potential to greatly influence the treatment of teenage violence. this could lead to the general acceptance and implementation of mindfulness-based self-compassion, making it accessible at a reasonable cost. the study's brevity and specificity hold promise for broader implementation. a significant gap exists in the literature concerning brief mindfulness-based self-compassion interventions tailored specifically to address adolescent aggression. most existing studies have explored more extended interventions or general mindfulness programs, leaving a dearth of research on the effectiveness of concise, targeted interventions for adolescents dealing with aggression.

the study's focus on a brief mindfulness-based self-compassion intervention stands out as a resource-efficient and practical approach to addressing aggression in adolescents. this concise intervention's potential effectiveness offers the promise of a more accessible and cost-effective approach to addressing adolescent aggression, which is critical in our resource-constrained world. the study determined that the brief intervention is efficacious, enabling its adaptation and implementation in educational institutions, juvenile justice programs, and community organizations that work with belligerent adolescents. due to its versatility, the conclusions of the study can be directly applied to real-world issues. the salient feature of this method is in its explicit targeting of adolescent aggression. by prioritizing self-compassion and mindfulness, this program aids in the regulation of emotions and reduces aggression among young individuals. effective interventions have the potential to improve the psychological well-being, emotional control, and interpersonal connections of adolescents who display aggressive behavior. this study has the potential to make mindfulness-based self-compassion practices more easily available to a greater number of adolescents. this might lead to the development of practical and cost-effective solutions that promote emotional well-being and decrease aggressiveness. these strategies would have long-lasting advantages.

Eligibility criteria:
inclusion criteria: 1. students' age range of 13 to 19 years 2. symptoms of aggression. exclusion criteria: students who are not willing to participate

Keywords: aggression self compassion adolescent
non invasive ventilation : efficacy of a new ventilatory mode in patients with ohs

Conditions: Obesity Hypoventilation Syndrome

Summary: in 2012, it has announced the availability of the new ventilator (bipap- a40), which could offer potential advantages over fixed level pressure support, in particular, in patients with obesity hypoventilation syndrome (ohs). one of the key benefits of the bipap a40 is an innovative ventilation mode called avaps-ae, which automatically maintains airway patency while delivering the correct level of ventilation each user requires, whatever their body position or sleep stage. avaps-ae mode is also aimed to help the clinicians during the initial titration of therapy, while providing long term comfort and assuring therapy compliance. however, studies on the physiologic and clinical effects have not yet been performed. the aim of our singled-blind randomised multicentre controlled trial is to prospectively investigate the effects of bipap with the spontaneous/timed (s/t) or the avaps-ae ventilation mode over 8 weeks on sleep quality, ventilation pattern, gas exchange, symptoms, body composition, level of physical activity and health-related quality of life in ohs patients.

efficacy on sleep quality, symptoms, physical activity and quality of life

Eligibility criteria:
inclusion criteria: * man or woman, stable patient with obesity hypoventilation syndrome, naives of non invasive ventilation. * paco2 ≥ 45 mmhg. * pao2 \< 70 mmhg * bmi ≥ 30kg. m2 exclusion criteria: * chronic obstructive pulmonary disease * neuromuscular disease * scoliosis * cardiac insufficiency * significant psychiatric disease * sleep apnea syndrome with central apnea index \> 10% * treatment with benzodiazepines at the inclusion
buprenorphine/naloxone for treatment of opiate dependence - 9

Conditions: Opioid-Related Disorders

Summary: the purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate-dependence treatment.


Eligibility criteria:
inclusion criteria: m/f ages 21-50. meet dsm-iv criteria for opiate dependence. agree to conditions of the study and sign informed consent. exclusion criteria: psychiatric disorder that requires medication therapy. history of seizures. pregnant and/or nuring women. dependence on etoh or benzodiazepines or other sedative/hypnotics. acute hepatitis. other medical condtions that deem participation to be unsafe.

Keywords: opioid dependence
the pharmacokinetics study of single and multiple dose of sp2086 in healthy volunteers

Conditions: Type 2 Diabetes

Summary: sp2086 is a novel inhibitor of dipeptide base peptidase 4, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. in this single-dose and multiple-dose study the investigators evaluated the safety, tolerability and pharmacokinetics profiles of sp2086 in healthy volunteers.


Eligibility criteria:
inclusion criteria: * bmi(a measure of a person's weight in relation to height)is between 19 and 26 kg/m2,and the weight is equal or less than 100kg. * without the history of cardiovascular diseases,liver diseases,kidney diseases,gastrointestinal tract diseases,mental nerve diseases and drug allergy. * be willing to accept physical contraception. * sign the informed consents voluntarily and ensure to completed the study. exclusion criteria: * known allergy to sp2086 or any of the excipients of the formulation of sp2086; * ever occured myocardial infarction,acute coronary syndrome, transient ischemic attack. * the b hepatitis surface antigen or hepatitis c antibody or syphilis antibody or hiv antibody was positive. * had participated three or more clinical trial in one year or had participated one time clinical medicine in one month of screening. * have the history of blood donation in 3 months of screening or received the blood transfusion in 1 months of screening. * have the history of tobacco,alcohol or drug abuse. * history of or current clinically significant medical illness as determined by the investigator.
concussion in motor vehicle accidents: the concussion identification index

Conditions: Motor Vehicle Accidents; TBI (Traumatic Brain Injury); Brain Contusion; Brain Injuries; Cortical Contusion; Concussion Mild; Cerebral Concussion; Brain Concussion; Accidents, Traffic; Traffic Accidents; Traumatic Brain Injury With Brief Loss of Consciousness; Traumatic Brain Injury With no Loss of Consciousness; Traumatic Brain Injury With Loss of Consciousness

Summary: the primary goal of this study is to provide clinicians with a brief, patient self-administer instrument yielding a single composite score that reliably correlates with objective findings on standardized neurocognitive assessment for concussion.

this phase 2 study, concussion in motor vehicle accidents - the concussion identification index (cidi), focuses on the psychometric properties of the relationship between acute injury events, i.e. head impact, loss of consciousness (loc), and post-traumatic amnesia (pta), commonly reported post-crash signs and symptoms, and neurocognitive outcomes. cohort 1 is the validation group and will be used to confirm the optimal cut-off score of the concussion identification index (cidi) with the score on the impact. cohort 2 is the cross-validation group.

Eligibility criteria:
inclusion criteria: * patients injured in a motor-vehicle related accident exclusion criteria: * age younger than 10 years old or older than 60 years of age * patients who presented for initial evaluation of injuries greater than 90 days after mva occurred * patients who declined to take a computerized neurocognitive test battery * patients who were not fluent in either english or spanish

Keywords: mild traumatic brain injury
systemic sclerosis and jak inhibitors : emphasis on macrophages

Conditions: Systemic Sclerosis

Summary: the sclero-jak project aims to assess the impact of a jak1/2 inhibitor (ruxolitinib) on activation states of monocytes-derived macrophages (mdm) from systemic sclerosis (ssc) patients

systemic sclerosis is a fibrotic and inflammatory chronic autoimmune disorder with no disease modifiying drug available to date. jak inhibitors may represent a relevant therapeutic candidate for this disease; the primary objective of this study is to characterize the impact of ruxolitinib (a jak ½ inhibitor) on the prof-fibrotic properties of mdm from ssc patients in vitro. the primary outcome will be the concentration of ccl18 evaluate by elisa in the condition media of mdm from ssc patients pre treated or not in vitro by ruxolitinib. the secondary objectives : 1. to characterize the impact of ruxolitinib on other pro-inflammatory or pro-fibrotic cytokines 2. to characterize the impact of ruxolitinib on membrane expression of macrophagic polarization markers of mdm from ssc patients 3. to evaluate the impact of ruxolitinib on the phenotype of mdm from healthy donors exposed in vitro to the serum of ssc patients. 4. to determine the variability of the effects of ruxolitinib on mdm of ssc patients depending on key clinical characteristics (diffuse versus limited ssc, patients with or without interstitial lung disease ild) the secondary outcomes : 1. elisa of the following cytokine evaluated in the condition media of ssc mdm pre-treated or not with ruxolitinib : pdgfbb, il-6, cxcl10, cxcl4 2. membrane expression (flow cytometry) of the following markers expressed by ssc mdm pre-treated or not with ruxoltinib : cd204, cd206, cd163, cd86, cmhii, tlr4. 3. evaluation of the same cytokines and membrane markers in mdm from hd exposed to serum media of ssc patients. 4. variation of the effect of ruxolitinib on the primary outcome (ccl18 secreted in the condition media of mdm from ssc patients) in sub groups depending on the following characteristics : * auto antibodies (anticentromere, antitopoisomerase, anti rna polymerase iii or none) * modified rodnan skin score * digital ulcers (current or past) * pulmonary involvement (interstitial lung disease on ct scan) * heart involvement (pulmonary arterial hypertension on echocardiography)

Eligibility criteria:
inclusion criteria: * patients with systemic sclerosis according to the acr/eular 2013 classification criteria for systemic sclerosis or patients with systemic lupus according to the acr2019 classification criteria for systemic lupus * with informed consent for participation to the study exclusion criteria: * patients unable to consent * patients with anemia inferior to 7g/dl

Keywords: systemic sclerosis macrophage ruxolitinib
study of pantoprazole for sleepiness associated with acid reflux and sleep apnea

Conditions: Acid Reflux Disease; Obstructive Sleep Apnea

Summary: the purpose of this study is to determine if using pantoprazole decreases your daytime sleepiness and improves your reaction time when compared to using a placebo (sugar pill).

half of the patients enrolled in the study will begin the study taking pantoprazole. the other half will begin the study taking a placebo (sugar pill). there is an equal chance of being placed in either group. after two weeks, the patients will stop taking their first batch of medication to allow it to completely leave their bodies. then the patients will begin taking the other medication so that by the end of the study, each patient will have been treated with pantoprazole for two weeks and placebo for two weeks. at the end of each two weeks, patients will be asked to complete questionnaires regarding their daytime sleepiness and reflux symptoms. patients will also complete reaction time testing as a measure of daytime sleepiness.

Eligibility criteria:
inclusion criteria: * age 18 or older * daytime sleepiness (ess \>= 8) * mild to moderate osd (ahi\<=30) * symptoms of gerd * symptoms of acid reflux exclusion criteria: * pregnant or trying to become pregnant * depression or unstable psychiatric disorder * allergy to pantoprazole * taking a proton pump inhibitor within the last month * taking a histamine-2 receptor blocker within the last month * automobile or industrial accident due to daytime sleepiness * currently taking ketoconazole, itraconazole, ampicillin or iron salts * hypersecretory acid disorder (zollinger-ellison syndrome) * active peptic ulcer disease * severe concomitant disease of another major body system * malignancy in the past 5 years * current abuse of alcohol, medication or drugs * sedative medications * additional treatment for obstructive sleep apnea (i.e. cpap or surgery)

Keywords: acid reflux obstructive sleep apnea daytime sleepiness
a clinical trial of the vessel sealing system (ligasure) in azygoportal disconnection and splenectomy in patients with portal hypertension

Conditions: Liver Cirrhosis

Summary: the aim of this trial was to verify the efficiency of a new surgical device (the ligasure vessels sealing system) in esophagogastric decongestion and splenectomy in patients with portal hypertension.

bleeding from esophageal and gastric cardia varices is the major life threatening complication in patients with portal hypertension. patients with portal hypertension have a mortality rate of 30%-50% at the first episode of esophagogastric variceal rupture. the associated 1-year mortality rate is reported to be 75%. the ideal treatment for gastric varices should effectively control bleeding and improve the liver function to optimum levels. although endoscopic treatments have showed great promise for esophageal varices, there is still controversy regarding the treatment of gastric varices. hepatic encephalopathy remain a dominant problems after transjugular intrahepatic portosystemic shunt placement (tips) and surgical shunts. a meta-analysis has shown that the incidence of hepatic encephalopathy and mortality was increased significantly either in nonselective or selective shunt operations. esophagogastric decongestion and splenectomy with or without esophageal transaction were the fundamental operation performed in our department for patients with portal hypertension. patients under the azygoportal devascularization methods revealed reduction of the encephalopathy as well as diminished rebleeding rates. the crucial point of the procedure is prevention of the brisk bleeding from the dilated vessels like enlarged azygoportal collaterals. conventional hand-tied ligatures can become dislodged and represent a foreign body, and more important, it is tedious and time-consuming. the ligasure vessel sealing system (valleylab, boulder, colorado) is a bipolar electrosurgical device, sealing vessels up to 7 mm in diameter, by denaturing collagen and elastin within vessel wall and surrounding connective tissue. this device was tested, with excellent results, in different fields of surgery (gastrointestinal, hepatopancreatobiliary, urologic, gynecologic, laparoscopic, etc), as demonstrated by several recently published studies. shamiyeh et al confirmed the reliability of ligasure for the closure of the veins in laparoscopic azygoportal disconnection procedure on the portal hypertension porcine model in 2005, there was no intra- or post-operative bleeding and no conversion to open surgery, and when more than 2 mm far from the thermal energy source, no collateral damage of the solid tissue such as stomach could be detected.

Eligibility criteria:
inclusion criteria: * patients with liver cirrhosis accompanied by portal hypertension and secondary hypersplenism due to hepatitis, alcoholic cirrhosis or schistosomiasis, who undergoing elective azygoportal disconnection and splenectomy exclusion criteria: * liver function as child-pugh c * hemoglobin \< 9 g/dl * ascites * abnormal coagulation

Keywords: ligasure vessel sealing system azygoportal disconnection splenectomy portal hypertension
trial to determine the safety and efficacy of influenza virus vaccine, trivalent, types a & b, live, cold-adapted (caiv-t) in healthy children

Conditions: Healthy

Summary: - the purpose of this study is to determine the efficacy of caiv-t in a diverse asian population aged from 6 months to less than 36 months, in tropical and temperate climates, against culture-confirmed influenza illness. in addition, the trial provides the opportunity to investigate the efficacy of caiv-t over multiple influenza seasons, and to investigate the effect of caiv-t on acute otitis media.


Eligibility criteria:
inclusion criteria: * who are greater than or equal to 6 months and less than 36 months of age at the time of enrollment, and in good health as determined by medical history, physical examination, and clinical judgment; * whose parent or legal guardian has provided written informed consent after the nature of the study has been explained; * who, along with their parent or legal guardian, will be available for the duration of the study (24 months); * whose parent/legal guardian can be reached by study staff for the post-immunization contacts \[via telephone, clinic or home visits\]. exclusion criteria: * whose parents or caregiver are perceived to be unreliable or difficult to contact for evaluation or study visits during the study period; * with any serious chronic disease (e.g., with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease; * with down's syndrome or other known cytogenetic disorders; * with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids; * who received any blood products, including immunoglobulin, in the period from six months prior to vaccination through to the conclusion of the study; * for whom there is intent to administer any other investigational vaccine or agent from one month prior to enrollment through to the conclusion of the study; * with an immunosuppressed or compromised individual living in the same household; * who, at any time prior to entry into this study, received a dose of any influenza vaccine (commercial or investigational); * who were administered any live virus vaccine within one month prior to study vaccination or expected receipt of another live virus within one month of vaccination in this study; * with a documented history of hypersensitivity to egg or egg protein, or any other component of the study vaccines or placebo; * with a respiratory illness with wheezing within two weeks prior to enrollment; * who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two weeks prior to enrollment or for which use is anticipated during the study; * with any medical conditions that in the opinion of the investigator might interfere with interpretation of the study results; note: a pregnant household member or day care provider is not considered a contraindication to enrollment.